Advaxis, Knight Therapeutics deal
Advaxis granted Knight exclusive rights to commercialize Advaxis’ product portfolio and future products in Canada and the right of first refusal to license most Advaxis product candidates in Israel.
Advaxis’ portfolio includes ADXS-HPV, a live Listeria monocytogenes-based immunotherapy expressing E7 transforming protein ( human papillomavirus-16; HpV16gp2), which has completed a Phase II trial to treat recurrent cervical cancer; ADXS-PSA, a prostate-specific antigen ( KLK3; PSA) incorporated in a live attenuated vector, which is in a Phase I/II trial to treat metastatic castration-resistant prostate cancer (CRPC); and ADXS-HER2, a live attenuated L. monocytogenes vaccine targeting EGFR2 (HER2; ErbB2; neu), which is in preclinical testing to treat cancer. ...